CLINICAL TRIALS PROFILE FOR MONOPRIL-HCT
✉ Email this page to a colleague
All Clinical Trials for MONOPRIL-HCT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00776334 ↗ | Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2002-10-01 | The objective of this study is to compare the relative bioavailability of fosinopril sodium 40 mg tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) with that of Monopril® in healthy adult subjects under fasting conditions. |
| NCT00776672 ↗ | Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2002-10-01 | The objective of this study is to compare the relative bioavailability of fosinopril sodium 40 mg tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) with that of Monopril® in healthy adult subjects under non-fasting conditions. |
| NCT00777972 ↗ | Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2003-03-01 | The objective of this study was to compare the relative bioavailability of Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited with that of Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet) in healthy adult subjects under fasting conditions |
| NCT00778713 ↗ | Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2003-03-01 | The objective of this study is to compare the relative bioavailability of Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited with that of Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet) in healthy adult subjects under non-fasting conditions. |
| NCT01669434 ↗ | Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery | Completed | University of Nebraska | Phase 4 | 2015-06-01 | Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MONOPRIL-HCT
Condition Name
Clinical Trial Locations for MONOPRIL-HCT
Trials by Country
Clinical Trial Progress for MONOPRIL-HCT
Clinical Trial Phase
Clinical Trial Sponsors for MONOPRIL-HCT
Sponsor Name
